SCHEMBL6197844

SCHEMBL6197844

CCOC(=O)c1ccc([N+](=O)[O-])c(NC(=O)COCCc2ccc(OCc3ccccc3)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.50
MAPT P10636 8/20 0.49
RAB9A P51151 4/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPK1 P28482 2/20 0.47
NPC1 O15118 2/20 0.47
POLB P06746 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
PKM P14618 2/20 0.46
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LNPEP Q9UIQ6 1/20 0.45
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6171232 0.90 MAPT (0.56) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL6168964 0.89 RAB9A (0.48) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL6169173 0.81 MAPT (0.65) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL6197847 0.80 LNPEP (0.52) LMNAMAPTRAB9AALDH1A1NPC1
SCHEMBL6169048 0.79 PKM (0.60) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL6169035 0.79 RAB9A (0.59) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL7592167 0.77 LNPEP (0.47) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL6170564 0.77 ALDH1A1 (0.62) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL7592177 0.76 RAB9A (0.46) LMNASMN1; SMN2MAPTRAB9AALDH1A1
SCHEMBL6172642 0.76 RAB9A (0.56) LMNASMN1; SMN2MAPTRAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0882718-B1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO (JP) 2005-08-31 EP disclosed
US-6352985-B1 CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-03-05 US disclosed
US-6166219-A Benzimidazole derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-12-26 US disclosed
EP-0882718-A1 BENZIMIDAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-09 EP disclosed